Artificial Pancreas Device System Market is Growing at a CAGR of 20.9% During 2018-2025: Defymed, TypeZero Technologies, Inc., Insulet Corporation, Bigfoot Biomedical, Inc., Medtronic, Dexcom, Inc., Admetsys, Beta Bionics, Cellnovo

The global artificial pancreas device systems market accounted to US$ 481.8 Mn in 2017 and is expected to grow at a CAGR of 20.9% during the forecast period 2018 - 2025, to account to US$ 2,168.1Mn by 2025.

The key market players of Artificial pancreas device systems market are Defymed, TypeZero Technologies, Inc., Insulet Corporation, Bigfoot Biomedical, Inc., Medtronic, Dexcom, Inc., Admetsys, Beta Bionics, Cellnovo, and Tandem Diabetes Care, Inc. among others. The market players are indulged into bringing new products to the market to keep to the pace of the competitive market nature. For instance, in February, 2018, Medtronic received the U.S. Food and Drug Administration (FDA) approval for new arm indication for the Guardian Sensor 3.

Get PDF sample copy: http://bit.ly/2WK26Gz

The market is likely to witness a rapid growth owing to factors such as growing prevalence of diabetes, developments by major players, and rise in demand for computerized systems for glycemic control. Additionally, the market is also likely to be accelerated by new product launches by market players that are presently in the pipeline. However, availability of alternatives for artificial pancreas device systems and high cost associated with these systems are expected to hinder the market growth in the coming years.

The threshold suspended device systems segment held the major market share among the type segment in the artificial pancreas device systems market

Global artificial pancreas device systems market, based on the type was segmented into control to range, control to target and threshold device systems. In 2017, the threshold suspended device systems segment held a largest market share of 71.5% of the artificial pancreas device systems market, by type. The threshold suspended device systems is the largest segment among the type segment in the artificial pancreas devices system market in 2017 and is also anticipated to hold the largest market in the year 2025. However, the control to target segment is the fastest growing segment and is accounted to grow at the CAGR of 21.4% over the forecast years.

North America holds the largest geographic market and it is expected to be the first highest revenue contributor throughout the forecast period. North America market is driven by the factors such as demand for artificial pancreas device systems in the region is anticipated to increase during the forecast years owing to factors such as increase in the number of patients with diabetes and rising demand for artificial pancreas device systems in the region.

Buy the complete report @ http://bit.ly/2WPkspK

Strategic Insights

Approvals and agreements were observed as the most adopted strategy in global artificial pancreas device systems industry. Few of the recent product launch and collaboration and others are listed below:

2018: In June, 2018, Insulet Corporation received FDA approval for its Omnipod DASH Insulin Management System.

2017: In January, 2017, Dexcom, Inc. expanded their global presence with a new Canadian headquarters in Burnaby, British Columbia. The headquarter aims to make it easier for more Canadians to get started with CGM.

2016: In February 2016, Cellnovo completed the full registration process required by the Italian Ministry of Health for medical devices and has been able to import and distribute the Cellnovo diabetes management system in Italy.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Web: https://www.theinsightpartners.com/

This release was published on openPR.